To include your compound in the COVID-19 Resource Center, submit it here.

Benralizumab: Phase IIa data

Data from 82 patients with moderate to severe COPD and an elevated sputum eosinophil count in the per protocol (PP) population of a double-blind, international Phase IIa trial in 101 patients showed that subcutaneous benralizumab missed

Read the full 362 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE